BMI View: Political instability and thus risk will remain elevated over the coming quarters in Brazil,
contributing to increasing uncertainty in terms of policy direction within the pharmaceuticals and
healthcare sector. Nonetheless, over a multiyear timeframe, the Br ..."
BMI View: The current state of political uncertainty will not shake Brazil's leading position as Latin
America's largest pharmaceutical and healthcare market. The Brazilian government has been committed to
improving the population's access to healthcare for decades. H ..."
BMI View: Brazil will continue to be the most important market for multinational pharmaceutical
companies in Latin America, despite growing financial tensions, increasing pricing pressure and generic
competition. Headline Expenditure Projections
BMI View: Continued focus on foreign investment along with the expansion of telemedicine and
governmental action to improve medical access will keep Brazil and appealing destination for drugmakers
and healthcare companies in coming years, particularly as the healthcar ..."
BMI View: Continued regulatory improvements, growing pharmaceutical and healthcare markets, and
increased favour for foreign investment will allow Brazil to maintain its position as the regional
outperformer in Latin America. However, low affordability and increasing ..."
BMI View: A thriving pharmaceutical market, active improvements to regulatory practices, and the
government's commitment to healthcare services will continue to make Brazil a regional outperformer. A
growing population and strategies for improved clinical research will ensure t ..."
BMI View: The Brazilian pharmaceutical market will continue to be the most attractive to multinational
pharmaceutical companies in Latin America. Strong government support, an improving regulatory regime
and significant private healthcare growth mean that the market p ..."
BMI View: The Brazilian pharmaceutical market remains the most attractive to multinational
pharmaceutical companies in Latin America. The expansion of healthcare coverage, driven by local
authorities, presents significant revenue-generating opportunities for drugmaker ..."
BMI View: Brazil's traditional commitment to healthcare improvement and growing middle-class
population present significant revenue-generating opportunities for multinationals in the country. The
Brazilian pharmaceutical market is now an integral part of all large pha ..."
BMI View: Although Sanofi's 'disappointing quarter' as well as currency devaluation in Brazil created
certain market unease, the sales performance of multinationals has remained positive. The increasing
demand for advanced medicines in the country continues to drive i ..."